These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 39061413

  • 1. Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life Study.
    Barbanti P, Orlando B, Egeo G, d'Onofrio F, Doretti A, Messina S, Autunno M, Messina R, Filippi M, Fiorentini G, Rotondi C, Bonassi S, Aurilia C.
    Brain Sci; 2024 Jun 30; 14(7):. PubMed ID: 39061413
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D'Amico D, Filippi M, Altamura C, Vernieri F, EARLY Study Group.
    Headache; 2021 Oct 30; 61(9):1351-1363. PubMed ID: 34309862
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
    Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group.
    J Headache Pain; 2021 May 03; 22(1):35. PubMed ID: 33941080
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A real-world prospective observational study of eptinezumab in Asian patients with migraine.
    Zhao YJ, Ong JJY, Sonu SK, Dang J, Ng CC, Herr KJ, Bose R, Jion YI.
    Headache; 2024 May 03; 64(7):810-824. PubMed ID: 38785386
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
    Barbanti P, Aurilia C, Egeo G, Proietti S, D'Onofrio F, Torelli P, Aguggia M, Bertuzzo D, Finocchi C, Trimboli M, Cevoli S, Fiorentini G, Orlando B, Zucco M, Di Clemente L, Cetta I, Colombo B, di Poggio MLB, Favoni V, Grazzi L, Salerno A, Carnevale A, Robotti M, Frediani F, Altamura C, Filippi M, Vernieri F, Bonassi S, ERT; for the Italian Migraine Registry study group.
    J Neurol; 2024 May 03; 271(5):2434-2443. PubMed ID: 38231271
    [Abstract] [Full Text] [Related]

  • 13. Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab.
    Blumenfeld A, Ettrup A, Hirman J, Ebert B, Cady R.
    BMC Neurol; 2022 Jul 08; 22(1):251. PubMed ID: 35804294
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study.
    Gonzalez-Martinez A, Sanz-García A, García-Azorín D, Rodríguez-Vico J, Jaimes A, Gómez García A, Casas-Limón J, Díaz de Terán J, Sastre-Real M, Membrilla J, Latorre G, Calle de Miguel C, Gil Luque S, Trevino-Peinado C, Quintas S, Heredia P, Echavarría-Íñiguez A, Guerrero-Peral Á, Sierra Á, González-García N, Porta-Etessam J, Gago-Veiga AB.
    Pain Med; 2024 Mar 01; 25(3):194-202. PubMed ID: 37847661
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real-life study.
    Zanandrea L, Messina R, Cetta I, Genovese F, Guerrieri S, Vernieri F, Altamura C, Cevoli S, Favoni V, Colombo B, Filippi M.
    Eur J Neurol; 2024 Dec 01; 31(12):e16410. PubMed ID: 39233446
    [Abstract] [Full Text] [Related]

  • 17. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.
    Grazzi L, Giossi R, Montisano DA, Canella M, Marcosano M, Altamura C, Vernieri F.
    J Headache Pain; 2024 Feb 02; 25(1):14. PubMed ID: 38308209
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Measuring interictal burden among people affected by migraine: a descriptive survey study.
    Hubig LT, Smith T, Williams E, Powell L, Johnston K, Harris L, L'Italien G, Coric V, Lloyd AJ, Lo SH.
    J Headache Pain; 2022 Aug 08; 23(1):97. PubMed ID: 35941572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.